Partnerships

RECEPTA has been establishing cooperation agreements with several centers of excellence, for continuity of its research & development activities. The following organizations are already part of this RECEPTA’s network of partner institutions:

Faculty of Medicine of USP

LIM-14 Laboratory of Investigation in Hepatic Pathology

The development of RECEPTA projects requires evaluation of the reactivity of its antibodies with tumoral and normal tissues, in studies with a comprehensive number of samples, for validation and extension of the results obtained by LCR researchers.

In this sense, an agreement was signed between RECEPTA and the Foundation of the Faculty of Medicine of the University of São Paulo (Fundação Faculdade de Medicina da Universidade de São Paulo – FMUSP) for the conduction of immunohistochemical studies by the Laboratory of Medical Investigation – 14 (Laboratório de Investigação Médica – 14 – LIM 14), linked to the Pathology Department. The project is coordinated by Dr. Venâncio Avancini F. Alves, PhD, full professor, a recognized specialist in immunohistochemistry. The project counts also on the collaboration of Achim Jungblüth, MD, researcher of the Ludwig Institute for Cancer Research (Instituto Ludwig de Pesquisa sobre o Câncer – LICR) in the Memorial Sloan-Kettering Cancer Center, New York.

Prof. Venâncio Avancini Alves, PhD

Medical doctor, with specialty in Pathologic Anatomy and Cytopathology. PhD and lecturer at the Faculty of Medicine of the University of São Paulo (FMUSP). Currently, he is full professor of the Department of Pathology of FMUSP and director of the Division of Pathological Anatomy of the Hospital of Clinics/FMUSP. He also coordinates the Laboratory of Medical Investigation in Hepatic Pathology of the same faculty. He was director of the Division of Pathology of Adolfo Lutz Institute.

LIM-24 Laboratory in Experimental Oncology

For determination of biodistribution of RECEPTA monoclonal antibodies, as well as of their potential for diagnostic use, radiolabeling of these antibodies and their evaluation into pre-clinical models are necessary. To reach this goal, RECEPTA is elaborating a research project in collaboration with Roger Chammas, MD, PhD, a researcher of the Department of Oncology of the Faculty of Medicine of the University of São Paulo (FMUSP), and counts on the advising and experience from Dr. Chaitanya Divgi, teacher of Columbia University (New York).

Roger Chamas, MD, PhD

He graduated in Medicine (1988) and concluded a doctorate in Biological and Biochemical Sciences (1993) by the University of São Paulo. He specialized in the area of Glycobiology at the University of California, San Diego (1994-1997). He was a visiting lecturer at Friedrich-Miescher Institut, Basilea, Switzerland (1991); Harvard School of Public Health, Boston, United States (1993); Federal University of São Paulo – Paulista School of Medicine, UNIFESP-EPM (1998-1999); and Moffitt Cancer Research Center, Tampa, United States (2011-2012). Since 2000, he works at the Faculty of Medicine of the University of Sao Paulo (FMUSP), where is currently a Full Professor of Oncology (area: Basic Oncology). He coordinates the Post-Graduation course in Oncology of USP (2007 – currently). Since 2001, he acts as an editor for the ‘Brazilian Journal of Medical and Biological Research’ (area: Cellular Biology); and, as an academic editor for PLoS One since 2009. His area of interest is Biochemistry and Cancer Cell Biology, operating in the fields of tumor progression, carbohydrate-dependent progression markers, and characterization of tumor microenvironments.

LIM-43 Laboratory in Nuclear Medicine

RECEPTA is elaborating a research project in collaboration with Dr. Carlos Buchpiguel, PhD, Director of the ‘Nuclear Medicine Service’ at the ‘Institute of Radiology’ of the Hospital of Clinics of the Faculty of Medicine of the University of Sao Paulo (FMUSP). This project will be developed also in collaboration with Dr. Chaitanya Divgi. The goal is to evaluate RECEPTA monoclonal antibodies’ potential as biomarkers for diagnostic or prognostic use, by means of radiolabeling and evaluation in clinical trials.

Federal University of São Paulo – UNIFESP

A pesquisa para identificação, desenho e caracterização de peptídeos com ação anti-tumorigênica é desenvolvida por pesquisadores da RECEPTA sob coordenação do Prof. Dr. Luiz Rodolpho Raja Gabaglia Travassos, Chefe da Unidade de Oncologia Experimental da UNIFESP.

Prof. Luiz Rodolpho Raja Gabaglia Travassos PhD

Graduated in Medicine by the Federal University of Rio de Janeiro (Universidade Federal do Rio de Janeiro) in 1962, Ph.D. in Sciences (Microbiology and Immunology) by the Federal University of Rio de Janeiro, in 1967. Post-Doctorate at Columbia University, New York, in the area of Immunochemistry and Glycobiology of fungi. Presently, he is Full Professor at Federal University of São Paulo (Universidade Federal de São Paulo – UNIFESP) and Head of the Experimental Oncology Unit. He has been a visiting professor at Columbia University (New York) and Visiting Researcher at Memorial Sloan Kettering Cancer Center (New York). He is a former member of several deliberative Councils, such as CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior or Coordination for the Improvement of Higher Education Personnel) and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico or National Council of Technological and Scientific Development), and presently is a member of the Directory Council of Butantan Institute (Butantan Institute). He received several awards, including commendation medals and the Grand Cross from the National Order of Scientific Merit (Ordem Nacional do Mérito Cientifico). He is a full member of the Brazilian Academy of Sciences. He has broad experience and scientific production in the area of eukaryotic cells immunology, with emphasis on Biochemotherapy of cancer and immunobiology of fungi, focusing specifically on Paracoccidioides brasiliensis and immunotherapy of paracoccidioidomycosis; glycobiology of pathogenic fungi; Trypanosoma cruzi and Chagas disease, antigenic compounds and diagnosis; murine melanoma and human tumors, peptides and peptidases. He has 200 publications in these scientific fields, having advised more than 40 graduate students.

Butantan

At Butantan Institute, a biomedical research center linked to the Secretary of Health of the State of São Paulo, research in molecular and cell biology and development of humanized antibodies was developed . This work was developed by RECEPTA researchers in collaboration with Ana Maria Moro, PhD, researcher of the institute and specialist in monoclonal antibodies.These studies were conducted in collaboration with the group of Gerd Ritter, PhD, of the Memorial Sloan-Kettering Cancer Center, New York. The purpose of the partnership with Butantan Institute was the development of GMP quality production of humanized antibodies in pilot scale, for the execution of Phase I and Phase II clinical trials.The collaboration agreement with the Institute is not limited to the generation of cell lines of interest to RECEPTA, but also includes the development of highly qualified human resources skilled in technologies strategically relevant to the country. The Institute will benefit by becoming qualified for the large scale production of humanized monoclonal antibodies, a capability for which there is a growing demand in the international market.

Ana Maria Moro, PhD

PhD in Biological Sciences (Genetics) at University of São Paulo (Brazil), specialized in Biochemical Genetics by University College London (England), and post-doc in Cell Biology by the Università degli Studi di Torino (Italy). Currently, she is director of the Laboratory of Monoclonal Antibodies of Butantan Institute and an advisor for Biotechnology students at USP. In the RECEPTA Biopharma- Butantan Institute joint project RECEPTA, she coordinated the group responsible for generation of cell lines producing humanized antibodies, building of master cell banks, and pilot scale production of antibodies. She also coordinated a FINEP-Butantan-RECEPTA project and its researchers.

Institute of Biosciences of the University of São Paulo

RECEPTA maintains a strict collaboration with Prof. Oswaldo Keith Okamoto, of the Department of Genetics and Evolutive Biology of the Institute of Biosciences of the University of São Paulo. Professor Okamoto’s experience in stem cells, gene expression, genomics, and tumor biology has been of high value in several RECEPTA projects, including target identification, assay development, and establishment of models for evaluation of antibodies.

Oswaldo Keith Okamoto, PhD

Prof. Okamoto is PhD by the Department of Biochemistry of the Institute of Chemistry of the University of São Paulo; he has also a post-doctoral training at Harvard University. He coordinated the Center for Experimental Research of the Albert Einstein Institute for Teaching and Research, from 2003 to 2006. He was an associate professor of Experimental Neurology at Federal University of São Paulo (UNIFESP). He has experience in biochemistry and molecular biology, with emphasis in genomics.

Institute of Biomedical Sciences of the University of São Paulo

icbRECEPTA maintains a collaboration with Prof. Dr. José Alexandre Barbuto, whose experience is dedicated to the study of relationships between immune system and neoplasias, in human patients, as well as in tumor experimental models, with investigations in immunotherapeutic approaches for cancer, based on dendritic cells.

José Alexandre Barbuto, PhD

Prof. Barbuto has graduated in Medicine by the University of São Paulo, has a master’s degree in Microbiology and Immunology by the Federal University of São Paulo, and a doctorate in Immunology by the University of São Paulo. As associate professor (ms-5) of the University of São Paulo, he is experienced in the Immunology area, with emphasis in Cellular Immunology, working mainly in the following themes: cancer, immunotherapy, dendritic cells, and macrophages.

Ludwig Cancer Research

The Ludwig Cancer Research (Instituto Ludwig de Pesquisa sobre o Câncer – LCR) is the RECEPTA Biopharma´s main partner RECEPTA. The four monoclonal antibodies (mAbs) licensed to the Company were developed by LCR researchers, with headquarters in New York. The Institute is a non-profit research organization, with an annual budget of US$80 million, which is dedicated to the understanding, treatment and control of cancer. It has branches in United States, Europe, Australia, and Brazil.

As RECEPTA´s shareholder, besides the licensing of the mAb intellectual property rights, the institute contributes with scientific and technological advices RECEPTA. The scientists collaborating directly with RECEPTA include Jonathan Skipper, PhD; Pär Olsson, PhD; Gerd Ritter, PhD; Eric Hoffman, PhD; Don DeRoo, PhD; and Achim Jungblüth, M.D., from the New York (USA) Branch of LICR, with a laboratory at Memorial Sloan-Kettering Cancer Center (MSKCC).The LCR São Paulo Branch, established in Brazil in 1983, is also one of RECEPTA’s partners. A major emphasis of the research at the LCR São Paulo Branch is on the identification of new tumor antigens and the generation of the corresponding mAbs. This project will be conducted in collaboration with Gerd Ritter, Ph.D. at the LCR’s New York Branch at the MSKCC.

G-Lab of Sloan School of Management – MIT

During 2005, RECEPTA Biopharma was one of the companies selected to participate in a program entitled Global Entrepreneurship Lab (G-Lab), maintained by the Sloan School of Management of the Massachusetts Institute of Technology (MIT). The G-Lab is a course offered to MBA students at Sloan, which combines classroom and training activities with the participation in companies previously selected for consultation projects by the companies registered in the program. Many of these companies are located in underdeveloped countries. From presentations of the projects given by the companies, the students choose to participate in those that are of most interest to them. An initial analysis is developed in-class by the students, which is followed by a trip to the company where they remain for 3 to 4 weeks to conclude their project. In this final stage, the study is conducted in close collaboration with the directors and managers of the companies.

The team of four MBA students from MIT/Sloan who worked on the RECEPTA project included Tracy Kim, Rehka Ravindra, Ikem Ugwu, and Debo Lukanmbi. This team formulated a business plan for RECEPTA, focusing on the increased value of each of the monoclonal antibodies in its portfolio. This consultancy project has been immensely valuable to RECEPTA, since it was based on a probability model generated specifically for research and development activities within the pharmaceutical industry, by researchers from the Sloan School itself. The G-Lab collaboration also prompted RECEPTA to reanalyze its business model and the elements influencing it in the market.

Further, in 2008, RECEPTA was again chosen by another group of G-Lab students, for a project on analysis of models according to large scale pharmaceutical companies, which included a reevaluation of the companies’ financial model. This MIT team was formed by Daniel Bendersky, Ricardo Solorzano, Oiang Han, and Khai Tou.

Studies and Projects Financer – FINEP

State of São Paulo Foundation for Research Support – FAPESP

National Council of Technological and Scientific Development – CNPq

 

lnbA RECEPTA established a partnership with the National Laboratory of Biosciences, linked to National Center of Research in Energy and Materials, for the installation of a laboratory for generation of producing cell lines and a Master Cell Bank (GMP). This laboratory will eliminate a bottleneck in the Brazilian biopharmaceuticals innovation chain.

Centers of Hospital Excellence

For development of its clinical trials, RECEPTA Biopharma structured partnerships with several reference hospital centers that have documented experience in the conduction of clinical trials, all over the Brazilian territory extension.
• Centro de Pesquisas Oncológicas de Santa Catarina – CEPON (Florianópolis – SC)
• Clínica de Oncologia de Porto Alegre – CLINIONCO (Porto Alegre – RS)
• Clínica Oxion (Belo Horizonte – MG)
• Fundação Amaral Carvalho (Jaú – SP)
• Hospital Alemão Oswaldo Cruz – HAOC (São Paulo – SP)
• Hospital da Baleia (Belo Horizonte – MG)
• Hospital das Clínicas da Universidade Federal de Goiás (Goiânia – GO)
• Hospital de Clínicas de Porto Alegre (Porto Alegre – RS)
• Hospital do Câncer de Barretos (Barretos – SP)
• Hospital Erasto Gaertner (Curitiba – PR)
• Hospital Israelita Albert Einstein (São Paulo – SP)
• Hospital São Lucas – PUC RS (Porto Alegre- SP)
• Hospital Sírio-Libanês (São Paulo – SP)
• Hospital Universitário Walter Cantídio da Universidade Federal do Ceará (Fortaleza – CE)
• Instituto Brasileiro de Controle do Câncer – IBCC (São Paulo – SP)
• Instituto do Câncer do Estado de São Paulo – ICESP (São Paulo – SP)
• Instituto Nacional do Câncer – INCA (Rio de Janeiro – RJ)
• Núcleo de Oncologia da Bahia – NOB (Salvador – BA)
• Hospital Santa Marcelina (São Paulo – SP)
• Hospital A.C. Camargo (São Paulo – SP)

Partnerships

RECEPTA has been setting collaboration agreements with various Centers of Excellence to accomplish its research and development activities. Know More.

RECEPTA in the Press

• Cutting-edge research breaks down barriers for new drugs. Read More. • ISTO É speaks about Brazilian investigations on cancer and cardiac and cerebral diseases. Read it. • SBMF – Monoclonal antibodies as meeting theme. Read More. • Época – Guide and Thinkers. Read More.Época Negócios – The big bang of bioindustry. Read More. • DBC NEWS - Prof. Dr. Perez in an interview and report from DBC-FM. Read More.